BIOMARKER:

ER positive

News alerts, weekly reports and conference planners

Entrez ID:

2099

Related biomarkers:

‹

›

ER positive	HER2 Negative Breast Cancer	ER positive	HER2 Negative Breast Cancer	RAD1901 Sensitive: B - Late Trials ESMO 2022 - 3 weeks (New B) RAD1901 Sensitive : B ESMO 2022 - 3wk	RAD1901 Sensitive: B - Late Trials ESMO 2022 - 3 weeks RAD1901 Sensitive : B ESMO 2022 - 3 weeks - (New B)
ER positive	Estrogen Receptor Positive Breast Cancer	ER positive	Estrogen Receptor Positive Breast Cancer	fulvestrant Sensitive: A1 - Approval fulvestrant Sensitive : A1	fulvestrant Sensitive: A1 - Approval fulvestrant Sensitive : A1
ER positive	Estrogen Receptor Positive Breast Cancer	ER positive	Estrogen Receptor Positive Breast Cancer	exemestane Sensitive: A1 - Approval exemestane Sensitive : A1	exemestane Sensitive: A1 - Approval exemestane Sensitive : A1
ER positive	Estrogen Receptor Positive Breast Cancer	ER positive	Estrogen Receptor Positive Breast Cancer	toremifene Sensitive: A1 - Approval toremifene Sensitive : A1	toremifene Sensitive: A1 - Approval toremifene Sensitive : A1
ER positive	HER2 Positive Breast Cancer	ER positive	HER2 Positive Breast Cancer	trastuzumab + lapatinib Sensitive: A2 - Guideline trastuzumab + lapatinib Sensitive : A2	trastuzumab + lapatinib Sensitive: A2 - Guideline trastuzumab + lapatinib Sensitive : A2
ER positive	HER2 Negative Breast Cancer	ER positive	HER2 Negative Breast Cancer	letrozole Sensitive: A2 - Guideline letrozole Sensitive : A2	letrozole Sensitive: A2 - Guideline letrozole Sensitive : A2
ER positive	Uterine Corpus Leiomyosarcoma	ER positive	Uterine Corpus Leiomyosarcoma	Aromatase inhibitor Sensitive: A2 - Guideline Aromatase inhibitor Sensitive : A2	Aromatase inhibitor Sensitive: A2 - Guideline Aromatase inhibitor Sensitive : A2
ER positive	HER2 Negative Breast Cancer	ER positive	HER2 Negative Breast Cancer	anastrozole Sensitive: A2 - Guideline anastrozole Sensitive : A2	anastrozole Sensitive: A2 - Guideline anastrozole Sensitive : A2
ER positive	Male Breast Cancer	ER positive	Male Breast Cancer	tamoxifen Sensitive: A2 - Guideline tamoxifen Sensitive : A2	tamoxifen Sensitive: A2 - Guideline tamoxifen Sensitive : A2
ER positive	HER2 Positive Breast Cancer	ER positive	HER2 Positive Breast Cancer	neratinib Sensitive: A2 - Guideline neratinib Sensitive : A2	neratinib Sensitive: A2 - Guideline neratinib Sensitive : A2
ER positive	HER2 Negative Breast Cancer	ER positive	HER2 Negative Breast Cancer	CDK6 inhibitor Sensitive: A2 - Guideline CDK6 inhibitor Sensitive : A2	CDK6 inhibitor Sensitive: A2 - Guideline CDK6 inhibitor Sensitive : A2
ER positive	HER2 Negative Breast Cancer	ER positive	HER2 Negative Breast Cancer	CDK4 inhibitor Sensitive: A2 - Guideline CDK4 inhibitor Sensitive : A2	CDK4 inhibitor Sensitive: A2 - Guideline CDK4 inhibitor Sensitive : A2
ER positive	Uterine Corpus Leiomyosarcoma	ER positive	Uterine Corpus Leiomyosarcoma	medroxyprogesterone Sensitive: A2 - Guideline medroxyprogesterone Sensitive : A2	medroxyprogesterone Sensitive: A2 - Guideline medroxyprogesterone Sensitive : A2
ER positive	Uterine Corpus Leiomyosarcoma	ER positive	Uterine Corpus Leiomyosarcoma	megestrol Sensitive: A2 - Guideline megestrol Sensitive : A2	megestrol Sensitive: A2 - Guideline megestrol Sensitive : A2
ER positive	HER2 Negative Breast Cancer	ER positive	HER2 Negative Breast Cancer	gimeracil/oteracil/tegafur Sensitive: B - Late Trials gimeracil / oteracil / tegafur Sensitive : B	gimeracil/oteracil/tegafur Sensitive: B - Late Trials gimeracil / oteracil / tegafur Sensitive : B
ER positive	HER2 Negative Breast Cancer	ER positive	HER2 Negative Breast Cancer	palbociclib Sensitive: B - Late Trials palbociclib Sensitive : B	palbociclib Sensitive: B - Late Trials palbociclib Sensitive : B
ER positive	HER2 Positive Breast Cancer	ER positive	HER2 Positive Breast Cancer	trastuzumab Sensitive: B - Late Trials trastuzumab Sensitive : B	trastuzumab Sensitive: B - Late Trials trastuzumab Sensitive : B
ER positive	HER2 Negative Breast Cancer	ER positive	HER2 Negative Breast Cancer	GDC-0032 Sensitive: B - Late Trials GDC-0032 Sensitive : B	GDC-0032 Sensitive: B - Late Trials GDC-0032 Sensitive : B
ER positive	HER2 Negative Breast Cancer	ER positive	HER2 Negative Breast Cancer	ribociclib Sensitive: B - Late Trials ribociclib Sensitive : B	ribociclib Sensitive: B - Late Trials ribociclib Sensitive : B
ER positive	Estrogen Receptor Positive Breast Cancer	ER positive	Estrogen Receptor Positive Breast Cancer	palbociclib Sensitive: B - Late Trials palbociclib Sensitive : B	palbociclib Sensitive: B - Late Trials palbociclib Sensitive : B
ER positive	HER2 Negative Breast Cancer	ER positive	HER2 Negative Breast Cancer	EC-P Sensitive: B - Late Trials EC-P Sensitive : B	EC-P Sensitive: B - Late Trials EC-P Sensitive : B
ER positive	Estrogen Receptor Positive Breast Cancer	ER positive	Estrogen Receptor Positive Breast Cancer	RAD1901 Sensitive: B - Late Trials RAD1901 Sensitive : B	RAD1901 Sensitive: B - Late Trials RAD1901 Sensitive : B
ER positive	HER2 Negative Breast Cancer	ER positive	HER2 Negative Breast Cancer	OP-1250 Sensitive: B - Late Trials OP-1250 Sensitive : B	OP-1250 Sensitive: B - Late Trials OP-1250 Sensitive : B
ER positive	HER2 Negative Breast Cancer	ER positive	HER2 Negative Breast Cancer	exemestane Sensitive: C1 - Off-label exemestane Sensitive : C1	exemestane Sensitive: C1 - Off-label exemestane Sensitive : C1
ER positive	HER2 Negative Breast Cancer	ER positive	HER2 Negative Breast Cancer	fulvestrant Sensitive: C1 - Off-label fulvestrant Sensitive : C1	fulvestrant Sensitive: C1 - Off-label fulvestrant Sensitive : C1
ER positive	Breast Cancer	ER positive	Breast Cancer	capecitabine Sensitive: C2 – Inclusion Criteria capecitabine Sensitive : C2	capecitabine Sensitive: C2 – Inclusion Criteria capecitabine Sensitive : C2
ER positive	Estrogen Receptor Positive Breast Cancer	ER positive	Estrogen Receptor Positive Breast Cancer	Z-endoxifen hydrochloride Sensitive: C2 – Inclusion Criteria Z-endoxifen hydrochloride Sensitive : C2	Z-endoxifen hydrochloride Sensitive: C2 – Inclusion Criteria Z-endoxifen hydrochloride Sensitive : C2
ER positive	Estrogen Receptor Positive Breast Cancer	ER positive	Estrogen Receptor Positive Breast Cancer	SAR439859 Sensitive: C2 – Inclusion Criteria SAR439859 Sensitive : C2	SAR439859 Sensitive: C2 – Inclusion Criteria SAR439859 Sensitive : C2
ER positive	Ovarian Cancer	ER positive	Ovarian Cancer	ribociclib Sensitive: C2 – Inclusion Criteria ribociclib Sensitive : C2	ribociclib Sensitive: C2 – Inclusion Criteria ribociclib Sensitive : C2
ER positive	HER2 Negative Breast Cancer	ER positive	HER2 Negative Breast Cancer	capecitabine Sensitive: C2 – Inclusion Criteria capecitabine Sensitive : C2	capecitabine Sensitive: C2 – Inclusion Criteria capecitabine Sensitive : C2
ER positive	HER2 Negative Breast Cancer	ER positive	HER2 Negative Breast Cancer	ZN-c5 Sensitive: C2 – Inclusion Criteria ZN-c5 Sensitive : C2	ZN-c5 Sensitive: C2 – Inclusion Criteria ZN-c5 Sensitive : C2
ER positive	HER2 Negative Breast Cancer	ER positive	HER2 Negative Breast Cancer	CB-228 Sensitive: C2 – Inclusion Criteria CB-228 Sensitive : C2	CB-228 Sensitive: C2 – Inclusion Criteria CB-228 Sensitive : C2
ER positive	HER2 Negative Breast Cancer	ER positive	HER2 Negative Breast Cancer	H3B-6545 Sensitive: C2 – Inclusion Criteria H3B-6545 Sensitive : C2	H3B-6545 Sensitive: C2 – Inclusion Criteria H3B-6545 Sensitive : C2

ER positive

Associations